bioAffinity Technologies (BIAF) Q2 2024 Earnings Report

Summary of QQ2 2024 performance for bioAffinity Technologies (BIAF): The company reported quarterly revenue of USD 2.398 million, marking a substantial year-over-year jump from the prior-year quarter driven by a very low base. Gross margin improved to 41.28%, but the quarter ended with a substantial net loss of USD 2.11 million and negative EBITDA of USD 1.93 million, reflecting ongoing operating expenses as the company advances its noninvasive diagnostics and targeted therapies programs. Operating cash flow remained negative at USD -1.53 million, with free cash flow also negative at USD -1.56 million, underscoring a liquidity-tight position despite a modest cash balance of USD 0.80 million at quarter-end. The balance sheet shows total assets of USD 6.66 million and total liabilities of USD 3.22 million, with a stockholders’ equity of USD 3.43 million and a net debt position of USD 1.06 million. Near-term liquidity is a focal point, as the company relies on ongoing financing or significant top-line growth to extend its cash runway.

Key takeaway for investors: BioAffinity’s topline is beginning to demonstrate meaningful growth on a very small base, and gross margins have improved, signaling potential efficiency gains in production and commercialization. However, the lack of profitability, ongoing cash burn, and a tight liquidity position imply elevated execution risk and the need for external financing or accelerated, milestone-driven revenue progression to sustain operations beyond the near term. The company’s strategic value hinges on the commercialization potential of CyPath lung and progress in its targeted therapies pipeline, alongside prudent cost management and disciplined capital allocation.